Cerevel Therapeutics (CERE) Stock Forecast & Price Target

$44.62

+0.22 (+0.50%)

(As of 07/26/2024 ET)

Cerevel Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 9 Analyst Ratings

Based on 9 Wall Street analysts who have issued ratings for Cerevel Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 9 analysts, 8 have given a hold rating, and 1 has given a buy rating for CERE.

Consensus Price Target

$42.67
-4.38% Downside

High Forecast	$45.00
Average Forecast	$42.67
Low Forecast	$31.00

According to the 9 analysts' twelve-month price targets for Cerevel Therapeutics, the average price target is $42.67. The highest price target for CERE is $45.00, while the lowest price target for CERE is $31.00. The average price target represents a forecasted downside of -4.38% from the current price of $44.62.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Hold	Hold	Hold	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)	8 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	8 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$42.67	$42.67	$41.40	$34.80
Forecasted Upside	-4.38% Downside	15.16% Upside	13.31% Upside	27.89% Upside

Get Cerevel Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter.

Ad Unstoppable Prosperity

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

CERE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CERE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cerevel Therapeutics Stock vs. The Competition

Type	Cerevel Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.11	2.72	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-4.38% Downside	3,123.46% Upside	9.10% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/16/2024	Mizuho 2 of 5 stars		Boost Target	Neutral ➝ Neutral	$25.00 ➝ $45.00	+5.71%
12/28/2023	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Neutral ➝ Neutral	$25.00 ➝ $45.00	+6.38%
12/22/2023	Jefferies Financial Group 2 of 5 stars		Reiterated Rating	Buy ➝ Hold	$40.00 ➝ $45.00	+8.72%
12/8/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform	$45.00	+9.41%
12/7/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Tsao Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$41.00 ➝ $45.00	+9.78%
12/7/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Duncan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$38.00 ➝ $45.00	+21.85%
Get the Latest News and Ratings for CERE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
12/7/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Neutral	$33.00 ➝ $45.00	+21.85%
11/2/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$42.00 ➝ $38.00	+52.73%
8/3/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$36.00 ➝ $31.00	+17.74%
5/4/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$30.00	-6.02%
3/16/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$22.00	-10.02%
11/1/2022	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$40.00	+43.06%
9/21/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$24.00 ➝ $28.00	+1.71%
9/12/2022	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:48 AM ET.

CERE Forecast - Frequently Asked Questions

What is Cerevel Therapeutics' forecast for 2024?: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Cerevel Therapeutics is $42.67, with a high forecast of $45.00 and a low forecast of $31.00.
Should I buy or sell Cerevel Therapeutics stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last year. There are currently 8 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CERE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERE, but not buy additional shares or sell existing shares.
Does Cerevel Therapeutics's stock price have much upside?: According to analysts, Cerevel Therapeutics's stock has a predicted upside of 15.16% based on their 12-month stock forecasts.
Do Wall Street analysts like Cerevel Therapeutics more than its competitors?: Analysts like Cerevel Therapeutics less than other "medical" companies. The consensus rating for Cerevel Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CERE compares to other companies.